Entity

Time filter

Source Type


Sharma H.,Serum Institute of India Ltd | Yadav S.,Maulana Azad Medical College and Lok Nayak Hospital | Patil V.,Jawaharlal Nehru Medical College and Prabhakar Kore Hospital | Chacko B.,Sri Ramchandra University Medical College and Hospital | And 8 more authors.
Vaccine | Year: 2011

Both WHO and IAP encourage using combination vaccines, wherever feasible. The phase III trial reported here was conducted to assess and compare the immunogenicity, tolerability and safety of two quadravalent vaccines, Quadrovax ® (new vaccine), and TETRAct-Hib ® (available in the market) in a multicentre study, in India. In all, 361 infants aged 6-8 weeks were enrolled, out of which 339 completed the study. The vaccination was done at 6-10-14 weeks following EPI/WHO recommended immunization schedule. Blood samples were collected prior to the administration of first dose and one month after the third dose. Postvaccination, geometric mean titres for each component did not differ significantly between the single dose vial and multi dose vial subgroups and among the two study groups. Adverse events observed were within the range quoted in literature. Quadrovax ® vaccine manufactured by SIIL was found to be safe, immunogenic and non-inferior to the comparator vaccine. The quadravalent vaccine is best recommended in the second year of life when children receive their booster dose at 15-18 months. It can be given to infants during primary immunization series at 6, 10 and 14 weeks of age when Hepatitis B vaccine is given in a separate arm or to infants at 10 weeks who receive the Hepatitis B vaccine separately following the 0, 6 and 14 weeks or 0, 1 and 6 months schedule. © 2011 Elsevier Ltd. Source


Sharma H.J.,Serum Institute of India Ltd | Patil V.D.,Jawaharlal Nehru Medical College and Hospital | Lalwani S.K.,Bharati Vidyapeeth Deemed University | Manglani M.V.,Lokmanya Tilak Municipal Medical College and General Hospital | And 11 more authors.
Vaccine | Year: 2012

Background: Hib vaccine can be easily incorporated in EPI vaccination schedule as the immunization schedule of Hib is similar to that of DTP vaccine. To meet the global demand of Hib vaccine, SIIL scaled up the Hib conjugate manufacturing process. This study was conducted in Indian infants to assess and compare the immunogenicity and safety of DTwP-HB+Hib (Pentavac ®) vaccine of SIIL manufactured at large scale with the 'same vaccine' manufactured at a smaller scale. Methods: 720 infants aged 6-8 weeks were randomized (2:1 ratio) to receive 0.5ml of Pentavac ® vaccine from two different lots one produced at scaled up process and the other at a small scale process. Serum samples obtained before and at one month after the 3rd dose of vaccine from both the groups were tested for IgG antibody response by ELISA and compared to assess non-inferiority. Results: Neither immunological interference nor increased reactogenicity was observed in either of the vaccine groups. All infants developed protective antibody titres to diphtheria, tetanus and Hib disease. For hepatitis B antigen, one child from each group remained sero-negative. The response to pertussis was 88% in large scale group vis-à-vis 87% in small scale group. Non-inferiority was concluded for all five components of the vaccine. No serious adverse event was reported in the study. Conclusions: The scale up vaccine achieved comparable response in terms of the safety and immunogenicity to small scale vaccine and therefore can be easily incorporated in the routine childhood vaccination programme. © 2011 Elsevier Ltd. Source

Discover hidden collaborations